Default: Lung Cancer

ISSN: 0169-5002

Journal Home

Journal Guideline

Lung Cancer Q1 Unclaimed

Elsevier Ireland Ltd Netherlands
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Lung Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 123. It has an SJR impact factor of 1,705 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -


- €

Gold OA


Green OA

- €

Non OA


Lung Cancer


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)



Best articles

110 High-dose therapy with etopside, ifosfamide, carboplatin, and epirubicin (VIP-E) in small cell lung cancer (SCLC)

View more

127 Spirometric control following vinca alkaloids in patients receiving mitomycin

View more

134 Experiences with multimodal treatment for non small cell lung-cancer in a lung hospital

View more

139 Alternant chemotherapy (CT) with cisplatin, iphosphamide and mitomycin, vinorelbine in the treatment of non small cell lung cancer (NSCLC). Final results of a phase II cooperative study

View more

168 A pilot study of high dose chemotherapy and irradiation with NEUPOGEN (G-CSF) in limited disease small cell lung cancer (SCLC)

View more

173 Long-term follow-up in 46 patients (pts) with IIIA (clinical N2) non-small cell lung cancer (NSCLC) after neoadjuvant chemotherapy (CT)

View more

182 High dose doxorubicin, cisplatin and tamoxifen vs mesothelioma

View more

187 Chemotherapy with mitomycin (MMC), ifosphamid (Ifo), cisplatin (DDP) or vinorelbin (Vr) in palliative treatment (Thx) of patient (Pts) with NSCLC lung cancer (Lc)

View more

195 Neoadjuvant chemo-radiotherapy in locally advanced non small cell lung cancer

View more

221 IFN-a and retinoic acid maintenance therapy for SCLC

View more

229 The management of small cell lung cancer (SCLC) with alternating chemotherapeutic regimens CAV-PE

View more

248 High incidence of isolated brain metastases (CNSMets) following complete response (CR) in advanced non-small cell lung cancer (NSCLC): A new challenge

View more

250 Phase III study of the value of adding cisplatin (C) and etoposide (E) to radiation in patients with locally advanced squamous cell carcinoma of the lung (SQCL). A multicentric swedish study of 302 patients

View more

275 Anti-cachectic effect of clarithromycin in inoperable non-small cell lung cancer patients

View more

283 Phase II trial of perioperative paclitaxel plus granulocyte-colony stimulating factor in mediastinoscopy-staged IIIA-N2 non-small cell lung cancer

View more

291 Preoperative chemo-radiotherapy (CT-RT) using concurrent boost radiation (RT) and resection for good responders in stage IIIB (T4 or N3) non-small cell lung cancer (NSCLC): A feasibility study

View more

299 Reservoir system for bronchial arterial infusion against lung cancer patients: Part II - radiological and technical aspects of implantation of the system

View more

63 Navelbine (NVB), and fractionated doses of cisplatin (CDDP) - 20 mg/m2/5 days - in the management of advanced non-small cell lung cancer: An overview of 3 phase II trials

View more

71 Chemotherapy in advanced NSCLC: Randomised comparison of ifosfamid/vindesin versus mitomycin/ifosfamid/cisplatin: A preliminary report

View more

78 A phase II study of paclitaxel (Taxol®) and ifosfamide (Holoxan®) in advanced non-small cell lung cancer

View more

84 Carboplatin, etoposide and vincristine in SCLC: A comparison of treatment within clinical trial and off protocol

View more

A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer

View more

A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer

View more

A short radiotherapy course for locally advanced non-small cell lung cancer (NSCLC). Effective palliation and patients' convenience

View more


No comments ... Be the first to comment!